申请人:Howard Philip Wilson
公开号:US20100113425A1
公开(公告)日:2010-05-06
Compounds of the formula I:
or solvate thereof, wherein:
R
2
is an optionally substituted C
5-20
aryl group;
R
6
and R
9
are independently selected from H, R, OH, OR, SH, SR, NH
2
, NHR, NRR′, nitro, Me
3
Sn and halo;
where R and R′ are independently selected from optionally substituted C
1-12
alkyl, C
3-20
heterocyclyl and C
5-20
aryl groups;
R
7
is selected from H, R, OH, OR, SH, SR, NH
2
, NHR, NHRR′, nitro, Me
3
Sn and halo;
R″ is a C
3-12
alkylene group, which chain may be interrupted by one or more heteroatoms and/or aromatic rings;
X is selected from O, S, or NH;
z is 2 or 3;
M is a monovalent pharmaceutically acceptable cation;
R
2′
, R
6′
, R
7′
, R
9′
, X′ and M′ are selected from the same groups as R
2
, R
6
, R
7
, R
9
, X and M respectively, or M and M′ may together represent a divalent pharmaceutically acceptable cation.
化合物I的公式或其溶剂化物,其中:R2是可选取的取代基C5-20芳基;R6和R9分别选自H、R、OH、OR、SH、SR、NH2、NHR、NRR′、硝基、Me3Sn和卤素;其中R和R′分别选自可选取的取代基C1-12烷基、C3-20杂环基和C5-20芳基;R7选自H、R、OH、OR、SH、SR、NH2、NHR、NHRR′、硝基、Me3Sn和卤素;R″是C3-12烷基,其链可以被一个或多个杂原子和/或芳环中断;X选自O、S或NH;z为2或3;M是单价的医药上可接受的阳离子;R2'、R6'、R7'、R9'、X'和M'分别选自与R2、R6、R7、R9、X和M相同的基团,或M和M'可以一起表示双价的医药上可接受的阳离子。